logo-loader

Shares in NetScientific up strongly after portfolio company's drug is given Merck boost

Published: 09:38 03 Oct 2019 EDT

Netscientific PLC -

Shares in NetScientific PLC (LON: NSCI) doubled in value after it emerged that a drug developed by one of its portfolio companies will take a key role in a phase II clinical study planned by industry giant Merck.

PDS Biotechnology’s PDS0101 will be trialled in harness with Merck’s top-selling immunotherapy, KEYTRUDA, as a front-line treatment for recurrent or metastatic head and neck cancer and the high-risk human papillomavirus-16 infection. The move essentially fast-tracks PDS0101.

"This collaboration advancing PDS0101 into phase II studies clearly demonstrates the strength of the results from PDS's initial Phase I studies for PDS0101,” said Ian Postlethwaite, chief executive of NetScientific, which invested £1.76mln for a 14.85% shareholding in PDS.

"Merck is renowned in the field of immuno-oncology, and PDS0101 when working in combination with their leading treatment for cancer, KEYTRUDA®, has the potential to offer a new and exciting therapy for patients suffering from these devastating diseases."

In mid-afternoon trade the shares, which were ahead 100% at one point, were changing hands for 11.26p, up 80%.

NetScientific portfolio company PDS Biotechnology to advance lead candidate...

Frank Bedu-Addo, president and CEO of PDS Biotechnology Corporation (NASDAQ:PDSB), a NetScientific PLC (AIM:NSCI) portfolio company, tells Proactive's Stephen Gunnion that a recent US$35mln debt financing agreement provides the financial resources necessary to advance the company's clinical...

on 09/20/2022